(MGTX) MeiraGTx Holdings - Ratings and Ratios
Gene, Therapy, Ocular, Neurodegenerative, Xerostomia, Cell, Therapies
MGTX EPS (Earnings per Share)
MGTX Revenue
Description: MGTX MeiraGTx Holdings
MeiraGTX Holdings PLC is a clinical-stage genetic medicines company that focuses on developing treatments for patients with serious diseases, leveraging its expertise in gene therapy to address a range of conditions, including ocular, neurodegenerative, and systemic diseases.
The companys pipeline includes multiple therapies for various indications, such as inherited retinal diseases, large degenerative ocular diseases, Parkinsons disease, and xerostomia, with several programs in Phase 2 and preclinical stages. Notable assets include AAV-AQP1, AAV-GAD, AAV-RPE65, AAV-CNGB3, and AAV-CNGA3, targeting conditions like radiation-induced xerostomia, Parkinsons, and achromatopsia. Additionally, the company has a broad preclinical pipeline, including AAV-RDH12, AAV-BBS10, AAV-RetGC, and AAV-UPF1, targeting retinal dystrophy, Bardet-Biedl syndrome, and amyotrophic lateral sclerosis.
MeiraGTX has established strategic collaborations with prominent companies, including Johnson & Johnson Innovative Medicine and Hologen Limited, to co-develop and commercialize gene therapies for various indications, such as inherited retinal disease and Parkinsons. The companys partnerships enhance its capabilities and increase the potential for successful product development.
Based on the available technical and fundamental data, the stock price is likely to be influenced by the companys progress in its clinical trials and the success of its partnerships. With a current price of $6.67, the stock is above its 20-day, 50-day, and 200-day simple moving averages, indicating a positive trend. The average true range (ATR) is 5.58%, suggesting moderate volatility. With a market capitalization of $520.77M and a forward P/E of 1.61, the company is valued relatively low, potentially indicating undervaluation. Given the companys promising pipeline and partnerships, a potential forecast could be that the stock price will rise to $8.00 in the next 6-12 months, driven by positive clinical trial results and progress in its collaborations, potentially leading to a 20% increase from the current price.
MGTX Stock Overview
| Market Cap in USD | 603m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2018-06-08 |
MGTX Stock Ratings
| Growth Rating | 10.5% |
| Fundamental | 39.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 44.8% |
| Analyst Rating | 4.60 of 5 |
MGTX Dividends
Currently no dividends paidMGTX Growth Ratios
| Growth Correlation 3m | -4.4% |
| Growth Correlation 12m | 61.6% |
| Growth Correlation 5y | -75.2% |
| CAGR 5y | -1.77% |
| CAGR/Max DD 3y | -0.03 |
| CAGR/Mean DD 3y | -0.06 |
| Sharpe Ratio 12m | 0.54 |
| Alpha | 0.05 |
| Beta | 0.906 |
| Volatility | 53.85% |
| Current Volume | 331.4k |
| Average Volume 20d | 277.5k |
| Stop Loss | 6.8 (-7.2%) |
| Signal | -0.68 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-157.5m TTM) > 0 and > 6% of Revenue (6% = 2.28m TTM) |
| FCFTA -0.55 (>2.0%) and ΔFCFTA -8.00pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -16.75% (prev 785.1%; Δ -801.9pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.65 (>3.0%) and CFO -129.1m > Net Income -157.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 0.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (80.6m) change vs 12m ago 25.18% (target <= -2.0% for YES) |
| Gross Margin 26.56% (prev -70.99%; Δ 97.56pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 16.30% (prev 3.05%; Δ 13.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -11.26 (EBITDA TTM -132.2m / Interest Expense TTM 12.8m) >= 6 (WARN >= 3) |
Altman Z'' -21.43
| (A) -0.03 = (Total Current Assets 47.1m - Total Current Liabilities 53.4m) / Total Assets 198.7m |
| (B) -3.93 = Retained Earnings (Balance) -780.8m / Total Assets 198.7m |
| warn (B) unusual magnitude: -3.93 — check mapping/units |
| (C) -0.62 = EBIT TTM -144.7m / Avg Total Assets 232.7m |
| (D) -4.03 = Book Value of Equity -788.3m / Total Liabilities 195.8m |
| Total Rating: -21.43 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 39.37
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -16.92% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 25.82 = -2.50 |
| 5. Debt/Ebitda -0.58 = -2.50 |
| 7. RoE -315.6% = -2.50 |
| 8. Rev. Trend 34.46% = 2.58 |
| 9. EPS Trend 45.81% = 2.29 |
What is the price of MGTX shares?
Over the past week, the price has changed by -2.14%, over one month by -8.03%, over three months by +15.80% and over the past year by +71.66%.
Is MeiraGTx Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MGTX is around 7.07 USD . This means that MGTX is currently overvalued and has a potential downside of -3.55%.
Is MGTX a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MGTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 27.3 | 272.9% |
| Analysts Target Price | 27.3 | 272.9% |
| ValueRay Target Price | 7.9 | 7.8% |
Last update: 2025-09-12 04:40
MGTX Fundamental Data Overview
CCE Cash And Equivalents = 32.2m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 1.6147
P/S = 15.8913
P/B = 203.5647
Beta = 1.296
Revenue TTM = 37.9m USD
EBIT TTM = -144.7m USD
EBITDA TTM = -132.2m USD
Long Term Debt = 73.8m USD (from longTermDebt, last quarter)
Short Term Debt = 2.65m USD (from shortTermDebt, last quarter)
Debt = 76.4m USD (Calculated: Short Term 2.65m + Long Term 73.8m)
Net Debt = 48.3m USD (from netDebt column, last quarter)
Enterprise Value = 646.8m USD (602.6m + Debt 76.4m - CCE 32.2m)
Interest Coverage Ratio = -11.26 (Ebit TTM -144.7m / Interest Expense TTM 12.8m)
FCF Yield = -16.92% (FCF TTM -109.5m / Enterprise Value 646.8m)
FCF Margin = -288.7% (FCF TTM -109.5m / Revenue TTM 37.9m)
Net Margin = -415.4% (Net Income TTM -157.5m / Revenue TTM 37.9m)
Gross Margin = 26.56% ((Revenue TTM 37.9m - Cost of Revenue TTM 27.8m) / Revenue TTM)
Tobins Q-Ratio = -0.82 (set to none) (Enterprise Value 646.8m / Book Value Of Equity -788.3m)
Interest Expense / Debt = 3.97% (Interest Expense 3.03m / Debt 76.4m)
Taxrate = 21.0% (US default)
NOPAT = -144.7m (EBIT -144.7m, no tax applied on loss)
Current Ratio = 0.88 (Total Current Assets 47.1m / Total Current Liabilities 53.4m)
Debt / Equity = 25.82 (Debt 76.4m / last Quarter total Stockholder Equity 2.96m)
Debt / EBITDA = -0.58 (Net Debt 48.3m / EBITDA -132.2m)
Debt / FCF = -0.70 (Debt 76.4m / FCF TTM -109.5m)
Total Stockholder Equity = 49.9m (last 4 quarters mean)
RoA = -79.26% (Net Income -157.5m, Total Assets 198.7m )
RoE = -315.6% (Net Income TTM -157.5m / Total Stockholder Equity 49.9m)
RoCE = -117.0% (set to none) (Ebit -144.7m / (Equity 49.9m + L.T.Debt 73.8m))
RoIC = -117.4% (set to none) (NOPAT -144.7m / Invested Capital 123.3m)
WACC = 8.65% (E(602.6m)/V(679.0m) * Re(9.35%)) + (D(76.4m)/V(679.0m) * Rd(3.97%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 93.94 | Cagr: 5.51%
Discount Rate = 9.35% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -109.5m)
EPS Correlation: 45.81 | EPS CAGR: 107.9% | SUE: -0.04 | # QB: 0
Revenue Correlation: 34.46 | Revenue CAGR: -9.22% | SUE: -0.47 | # QB: 0
Additional Sources for MGTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle